Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.

Ligachem Biosciences Inc. landed another exclusive licensing deal to develop and commercialize antibody-drug conjugates (ADCs), this time with T-cell receptor therapy specialist Daan Biotherapeutics Inc. for a cancer-targeting antibody.

Dealmaking in the Asia Pacific (APAC) region took off this week, with the latest showcasing Genome & Co.’s licensing deal with Ellipses Pharma Ltd. for GENA-104, a phase I-ready immuno-oncology asset, under undisclosed terms Feb. 11.

Antibody-drug conjugates (ADCs) have demonstrated their effectiveness in a variety of solid tumors such as breast, lung, ovarian or bladder cancer and in hematological cancers too. However, in some cancer types, like pancreatic cancer, treatment with ADCs needs enhancement through more appropriate targets and payloads.

Bioray Pharmaceutical Co. Ltd. has announced clinical trial clearance in China by the National Medical Products Administration (NMPA) for BR-111 for injection for the treatment of ROR1-positive hematological malignancies and solid tumors.

Leukemic stem cells (LSCs) and stemness signatures contribute to minimal residual disease in patients with acute myeloid leukemia (AML), which is associated with an increased risk of relapse. The presence of LSCs predicts treatment success and, therefore, eliminating LSCs has been proposed as a promising strategy to avoid relapses.

A year after its $175 million IPO in 2024, Arrivent Biopharma Inc. picked up rights to develop and commercialize Lepu Biopharma Co. Ltd.’s antibody-drug conjugate (ADC) candidate, MRG-007, worldwide excluding the greater China region.

Arrivent Biopharma Inc. has entered into an exclusive license agreement with Lepu Biopharma Co. Ltd. for MRG-007, an antibody-drug conjugate (ADC) in development for gastrointestinal cancers.